Skip to main content

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab with and without Atezolizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

*May 2023*

The emergence of immune checkpoint inhibitors has dramatically altered the treatment landscape of stage IV NSCLC with some patients now experiencing unprecedented long-term survival after PD-1/PD-L1 therapy.

These individuals that benefit typically have smoking-induced lung tumors, while patients who have never smoked or have EGFR-driven NSCLC, generally possess tumors that are highly resistant to checkpoint inhibitors. Identifying effective therapeutic strategies that overcome immunotherapy resistance among these subgroups of patients remains a critical unmet need. This phase II trial is evaluating a strategy of adding atezolizumab to carboplatin, pemetrexed, and bevacizumab to determine if this regimen can improve outcomes in patients with stage IV non-squamous NSCLC who either have never smoked or have tumors with sensitizing EGFR mutations. This clinical trial (NCT03786692) is currently in progress and open at twelve U.S. sites through the National Comprehensive Cancer Network (NCCN). This trial opened in August 2019 and accrual is expected to be completed in the Fall of 2024. Read more.